for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

シノファーム・グループ

1099.HK

現在値

23.45HKD

変化

0.70(+3.08%)

出来高

7,294,316

本日のレンジ

22.80

 - 

23.65

52週レンジ

15.76

 - 

28.00

∙ 約20分前の相場を表示しています。

適時開示

BlackRock Inc Sold 1.6 Mln H-Shares In Sinopharm On May 31 - HKEX Filing

June 3 (Reuters) - Hong Kong stock exchange filing::BLACKROCK INC SOLD 1.6 MLN H-SHARES IN SINOPHARM <<<1099.HK>>> AT AVG PRICE OF HK$26.56 ($3.42) PER SHARE ON MAY 31 - HKEX FILING.BLACKROCK INC'S LONG POSITION IN SINOPHARM FALLS TO 6.99% FROM 7.11% - HKEX FILING.

Sinopharm Group QTRLY Net Profit Attributable RMB1.22 Billion

April 28 (Reuters) - Sinopharm Group Co Ltd <1099.HK>::QTRLY NET PROFIT ATTRIBUTABLE RMB1.22 BILLION VERSUS RMB812 MILLION.QTRLY TOTAL OPERATING REVENUE RMB120.27 BILLION VERSUS RMB94.40 BILLION.

Probi And Sinopharm Enter Strategic Partnership In China

March 29 (Reuters) - Sinopharm Group Co Ltd <1099.HK>::PROBI AND SINOPHARM ENTER STRATEGIC PARTNERSHIP IN CHINA.PROBI(®) AND SINOPHARM, ONE OF CHINA'S LARGEST PHARMACEUTICAL & HEALTHCARE COMPANIES ENTER A PARTNERSHIP TO EXPAND OFFERING OF PREMIUM PROBIOTIC OFFERINGS IN CHINESE MARKET.

Sinopharm Group Posts FY Profit Attributable RMB 7.19 Billion

March 22 (Reuters) - Sinopharm Group Co Ltd <1099.HK>::FY PROFIT ATTRIBUTABLE RMB 7.19 BILLION VERSUS RMB 6.25 BILLION.FY REVENUE RMB456.41 BILLION VERSUS RMB425.27 BILLION.PROPOSED FINAL DIVIDEND OF RMB0.69 PER ORDINARY SHARE.

BlackRock Inc's Long Position In Sinopharm Group Raises To 5.01% - HKEX Filing

March 12 (Reuters) - Hong Kong stock exchange filing::BLACKROCK INC BOUGHT 403,200 SHARES IN SINOPHARM GROUP <<<1099.HK>>> AT AVG PRICE OF HK$17.40 ($2.24) PER SHARE ON MARCH 9- HKEX FILING.BLACKROCK INC'S LONG POSITION IN SINOPHARM GROUP RAISES TO 5.01% FROM 4.98% - HKEX FILING.

BlackRock Inc's Long Position In Sinopharm Group Falls To 4.98% - HKEX Filing

March 11 (Reuters) - Hong Kog stock exchange filing::BLACKROCK INC'S LONG POSITION IN SINOPHARM GROUP <<<1099.HK>>> DECREASED TO 4.98% ON MARCH 8 FROM 5.18% - HKEX FILING.

Sinopharm Group Appoints Li Xiaojuan CFO

March 1 (Reuters) - Sinopharm Group Co Ltd <1099.HK>::APPOINTED LI XIAOJUAN AS CHIEF FINANCIAL OFFICER.APPOINTED ZHOU SONG AND CHEN ZHANYU AS VICE PRESIDENTS.JIANG XIUCHANG CEASED TO SERVE AS CHIEF FINANCIAL OFFICER.JIANG XIUCHANG WILL REMAIN AS VICE PRESIDENT.

BlackRock Inc's Long Position In Sinopharm Group Increases To 5.10% - HKEX Filing

Feb 24 (Reuters) - Hong Kong stock exchange filing: :BLACKROCK INC'S LONG POSITION IN SINOPHARM GROUP <<<1099.HK>>> INCREASED TO 5.10% ON FEB 19 FROM 4.92% - HKEX FILING.

Sinopharm Group Says Elected Yu Qingming As Chairman

Jan 14 (Reuters) - Sinopharm Group Co Ltd <1099.HK>::ELECTED YU QINGMING AS CHAIRMAN.

Sinopharm Group Co Says Li Zhiming Resigns as Chairman

Jan 12 (Reuters) - Sinopharm Group Co Ltd <1099.HK>::RECEIVED RESIGNATION FROM LI ZHIMING, CHAIRMAN OF BOARD.BOARD ELECTED YU QINGMING TO ACT AS CHAIRMAN OF BOARD.LI ZHIMING RESIGNED AS EXECUTIVE DIRECTOR.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up